Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Randomized Double-Blind Phase II Trial of Baby Exemestane Versus Baby Tamoxifen in Post-Menopausal Women at High Risk for Breast Cancer (BabyTEARS)

NCT07499999 is registered in ClinicalTrials.gov with Dana-Farber Cancer Institute as lead sponsor.

NCT NCT07499999
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07499999 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Randomized Double-Blind Phase II Trial of Baby Exemestane Versus Baby Tamoxifen in Post-Menopausal Women at High Risk for Breast Cancer (BabyTEARS)
Lead sponsor
Dana-Farber Cancer Institute
Phase
Phase 2
Overall status
Not yet recruiting
Start date
September 9, 2026
Completion date
August 31, 2028
Enrollment
140 (estimated)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

ataxia telangiectasia mutated gene mutation, atypical lobular hyperplasia, brca2 mutation, breast cancer, chek2 gene mutation, ductal carcinoma, estrogen-receptor-positive breast cancer